VALENCIA, Spain, Nov. 11, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today ...
US FDA grants rare paediatric designation to ARTHEx Biotech’s ATX-01 for the treatment of myotonic dystrophy type 1: Valencia, Spain Friday, November 8, 2024, 16:00 Hrs [IST] AR ...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, today announced that the U.S. Food and Drug ...
many patients who fit this depressive symptomatology indeed have features of bipolar II disorder. [2] This ongoing probing of variation within well-established mood-disorder entities promises ...